PSORS2
MCID: PSR017
MIFTS: 52

Psoriasis 2 (PSORS2)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Psoriasis 2

MalaCards integrated aliases for Psoriasis 2:

Name: Psoriasis 2 57 75 73
Psoriasis Vulgaris 75 73
Psoriasis 75 73
Psors2 57 75
Psoriasis, Susceptibility to, Type 2 40
Pv 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant

Miscellaneous:
variability in age of onset and severity of disease


HPO:

32
psoriasis 2:
Inheritance autosomal dominant inheritance


Classifications:



Summaries for Psoriasis 2

UniProtKB/Swiss-Prot : 75 Psoriasis 2: A common, chronic inflammatory disease of the skin with multifactorial etiology. It is characterized by red, scaly plaques usually found on the scalp, elbows and knees. These lesions are caused by abnormal keratinocyte proliferation and infiltration of inflammatory cells into the dermis and epidermis.

MalaCards based summary : Psoriasis 2, also known as psoriasis vulgaris, is related to pericardial effusion and guttate psoriasis, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Psoriasis 2 is CARD14 (Caspase Recruitment Domain Family Member 14), and among its related pathways/superpathways is Transcription Ligand-dependent activation of the ESR1/SP pathway. The drugs Ustekinumab and Dermatologic Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are hyperkeratosis and parakeratosis

Description from OMIM: 602723

Related Diseases for Psoriasis 2

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13

Diseases related to Psoriasis 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 664)
# Related Disease Score Top Affiliating Genes
1 pericardial effusion 28.8 ADA HIF1A
2 guttate psoriasis 12.6
3 pustular psoriasis 12.5
4 polycythemia vera 12.3
5 psoriasis 15, pustular 12.3
6 pustulosis palmaris et plantaris 12.2
7 psoriasis 6 12.2
8 psoriasis 3 12.1
9 psoriasis 4 12.1
10 psoriasis 5 12.1
11 psoriasis 8 12.1
12 psoriasis 10 12.1
13 psoriasis 12 12.1
14 mental retardation and psoriasis 12.0
15 psoriasis 9 12.0
16 pustulosis of palm and sole 11.9
17 psoriatic juvenile idiopathic arthritis 11.9
18 tranebjaerg svejgaard syndrome 11.7
19 psoriasis 1 11.7
20 impetigo herpetiformis 11.6
21 pulmonary valve stenosis 11.5
22 geographic tongue 11.4
23 parapsoriasis 11.4
24 pemphigus vulgaris, familial 11.4
25 persistent vegetative state 11.4
26 chronic recurrent multifocal osteomyelitis 11.3
27 subacute cutaneous lupus erythematosus 11.3
28 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 11.3
29 psoriasis 14, pustular 11.2
30 singleton-merten syndrome 1 11.1
31 systemic onset juvenile idiopathic arthritis 11.1
32 porphyria variegata 11.0
33 psoriasis 7 11.0
34 psoriasis 11 11.0
35 psoriasis 13 11.0
36 nail disorder, nonsyndromic congenital, 1 10.9
37 singleton-merten syndrome 2 10.9
38 temporomandibular ankylosis 10.9
39 primary cutaneous amyloidosis 10.9
40 combined immunodeficiency with skin granulomas 10.9
41 singleton-merten syndrome 10.9
42 polycythemia 10.4
43 rheumatoid arthritis 10.4
44 skin disease 10.3
45 malaria 10.3
46 pemphigus foliaceus 10.3
47 hepatitis 10.3
48 alopecia 10.3
49 myelofibrosis 10.3
50 essential thrombocythemia 10.3

Graphical network of the top 20 diseases related to Psoriasis 2:



Diseases related to Psoriasis 2

Symptoms & Phenotypes for Psoriasis 2

Symptoms via clinical synopsis from OMIM:

57
Skin Nails Hair Skin Histology:
hyperkeratosis
parakeratosis
epidermal acanthosis
follicular plugging
alternating orthokeratosis and parakeratosis (in some patients)
more
Skin Nails Hair Skin:
plaque-like scaling skin lesions
erythrodermic psoriasis (in some patients)
pustular psoriasis (in some patients)
skin atrophy, diffuse, in older patients

Skeletal:
arthritis, psoriatic (in some patients)


Clinical features from OMIM:

602723

Human phenotypes related to Psoriasis 2:

32
# Description HPO Frequency HPO Source Accession
1 hyperkeratosis 32 HP:0000962
2 parakeratosis 32 HP:0001036
3 scaling skin 32 HP:0040189
4 epidermal acanthosis 32 HP:0025092
5 psoriasiform dermatitis 32 HP:0003765

UMLS symptoms related to Psoriasis 2:


pruritus, exanthema, psoriasiform rash

Drugs & Therapeutics for Psoriasis 2

Drugs for Psoriasis 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ustekinumab Approved, Investigational Phase 3 815610-63-0
2 Dermatologic Agents Phase 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis Completed NCT02684357 Phase 3 ABBV-066;ustekinumab;placebo for ABBV-066;placebo for ustekinumab

Search NIH Clinical Center for Psoriasis 2

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Psoriasis 2

Anatomical Context for Psoriasis 2

MalaCards organs/tissues related to Psoriasis 2:

41
Skin, Testes, T Cells, Liver, Thyroid, Bone, Tongue

Publications for Psoriasis 2

Articles related to Psoriasis 2:

(show top 50) (show all 979)
# Title Authors Year
1
A Chinese cross-sectional study on depression and anxiety symptoms in patients with psoriasis vulgaris. ( 30293440 )
2019
2
Psoriasis vulgaris in a patient with pemphigus vulgaris on corticosteroid therapy. ( 29689136 )
2018
3
Relationship between etanercept and thyroid function in patients with psoriasis vulgaris. ( 29440950 )
2018
4
Auftreten einer Psoriasis vulgaris bei einem Patienten mit Pemphigus vulgaris unter Kortikosteroidtherapie. ( 29750447 )
2018
5
Concurrent development of psoriatic arthritis, drug-induced interstitial pneumonia, and increased anti-nuclear antibodies in a patient with psoriasis vulgaris undergoing adalimumab treatment. ( 30530442 )
2018
6
Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence. ( 30474868 )
2018
7
Differences in Palmoplantar Pustulosis and Psoriasis Vulgaris in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Treated with Biological Therapy. ( 30323005 )
2018
8
De Novo Psoriasis Vulgaris Diagnosed after Nivolumab Treatment for Refractory Hodgkin's Lymphoma, Completely Resolved after Autologous Hematopoietic Stem Cell Transplantation. ( 30410803 )
2018
9
Psoriasis vulgaris associated with systemic lupus erythematosus successfully treated with apremilast. ( 30536461 )
2018
10
Pemphigus Associated with Psoriasis Vulgaris: A Retrospective Study of Seven Patients and a Review of the Literature. ( 30390724 )
2018
11
Paradoxical exacerbation of latent interstitial pneumonia by secukinumab in a patient with psoriasis vulgaris. ( 30430554 )
2018
12
Serum Levels of Aryl Hydrocarbon Receptor, Cytochromes P450 1A1 and 1B1 in Patients with Exacerbated Psoriasis Vulgaris. ( 30394267 )
2018
13
Hochregulation der SLURP1-Immunfärbung in Läsionen von Psoriasis-vulgaris-Patienten entspricht dem Schweregrad der Erkrankung. ( 30395397 )
2018
14
Lesional upregulation of SLURP1 immunostaining parallels disease severity in psoriasis vulgaris patients. ( 30395407 )
2018
15
Serum YKL-40 in patients with psoriasis vulgaris treated by narrow-band UVB phototherapy. ( 30482111 )
2018
16
Association of ERAP1 gene polymorphisms with the susceptibility to psoriasis vulgaris: A case-control study. ( 30313118 )
2018
17
Expression of death receptor 3 (DR3) on peripheral blood mononuclear cells of patients with psoriasis vulgaris. ( 30341229 )
2018
18
Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature. ( 30349342 )
2018
19
Clinical and molecular evaluation of therapy with the use of cyclosporine A in patients with psoriasis vulgaris. ( 30350412 )
2018
20
Variants of CARD14 are predisposing factors for generalized pustular psoriasis (GPP) with psoriasis vulgaris but not for GPP alone in a Chinese population. ( 30387497 )
2018
21
Transforming growth factor-β1 gene polymorphism in psoriasis vulgaris. ( 30174452 )
2018
22
Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review. ( 30186132 )
2018
23
Mean platelet volume and platelet distribution width levels in patients with mild psoriasis vulgaris with metabolic syndrome. ( 30206448 )
2018
24
Treatment of psoriasis vulgaris using low-dose naltrexone. ( 30238048 )
2018
25
Efficacy, safety, and cost-effectiveness of all-trans retinoic acid/Clobetasol Propionate Compound Ointment in the treatment of mild to moderate psoriasis vulgaris: A randomized, single-blind, multicenter clinical trial. ( 30253049 )
2018
26
Evaluation of capillary pathologies by nailfold capillaroscopy in patients with psoriasis vulgaris: study protocol for a prospective, controlled exploratory study. ( 30099394 )
2018
27
Evaluation of epicardial adipose tissue volume and coronary artery calcification in Japanese patients with psoriasis vulgaris. ( 30152023 )
2018
28
Concurrence of psoriasis vulgaris and atopic eczema in a single patient exhibiting different expression patterns of psoriatic autoantigens in the lesional skin. ( 29984272 )
2018
29
NAT2 Gene Polymorphisms in Turkish Patients with Psoriasis Vulgaris. ( 29992137 )
2018
30
Metabolic Syndrome May Exacerbate Macular and Retinal Damage in Psoriasis Vulgaris. ( 29847216 )
2018
31
Efficacy and Safety of Tripterygium Wilfordii Hook F on Psoriasis Vulgaris: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( 29849698 )
2018
32
Association of NLRP1 and NLRP3 Polymorphisms with Psoriasis Vulgaris Risk in the Chinese Han Population. ( 29850521 )
2018
33
Association of Cytotoxic T Lymphocyte Antigen-4 Gene Polymorphisms with Psoriasis Vulgaris: A Case-Control Study in Turkish Population. ( 29850619 )
2018
34
Effect of low-dose acitretin treatment on pituitary hormones in psoriasis vulgaris: A retrospective study. ( 29855455 )
2018
35
S3-Leitlinie zur Therapie der Psoriasis vulgaris Update - Kurzfassung Teil 2 - Besondere Patientengruppen und spezielle Behandlungssituationen. ( 29873903 )
2018
36
S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 2 - Special patient populations and treatment situations. ( 29873906 )
2018
37
Density of mast cells and intensity of pruritus in psoriasis vulgaris: a cross sectional study. ( 29924253 )
2018
38
Methods Report: Update of the German S3 Guideline for the Treatment of Psoriasis vulgaris. ( 29750442 )
2018
39
S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment. ( 29750443 )
2018
40
S3-Leitlinie zur Therapie der Psoriasis vulgaris Update - Kurzfassung Teil 1 - Systemische Therapie. ( 29750455 )
2018
41
Evaluating Serum Levels of IL-33, IL-36, IL-37 and Gene Expression of IL-37 in Patients with Psoriasis Vulgaris. ( 29757591 )
2018
42
Mutational analysis of epidermal and hyperproliferative type I keratins in mild and moderate psoriasis vulgaris patients: a possible role in the pathogenesis of psoriasis along with disease severity. ( 29784039 )
2018
43
A case of anti-laminin γ1 (p200) pemphigoid with psoriasis vulgaris successfully treated with apremilast. ( 29619999 )
2018
44
Association of the novel susceptible locus rs9266150 with clinical features of psoriasis vulgaris in the Chinese Han population. ( 29630754 )
2018
45
Notch1 Signaling Regulates the Th17/Treg Immune Imbalance in Patients with Psoriasis Vulgaris. ( 29686529 )
2018
46
A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab. ( 29523055 )
2018
47
Variants at HLA-A, HLA-C, and HLA-DQB1 Confer Risk of Psoriasis Vulgaris in Japanese. ( 29031612 )
2018
48
Low incidence of hypercalcemia following combined calcipotriol hydrate/betamethasone dipropionate ointment treatment in Japanese patients with severe psoriasis vulgaris. ( 29076379 )
2018
49
The association of ERAP1 and ERAP2 single nucleotide polymorphisms and their haplotypes with psoriasis vulgaris is dependent on the presence or absence of the HLA-C*06:02 allele and age at disease onset. ( 29183862 )
2018
50
Integrative Approach to Psoriasis Vulgaris. ( 29261515 )
2018

Variations for Psoriasis 2

UniProtKB/Swiss-Prot genetic disease variations for Psoriasis 2:

75
# Symbol AA change Variation ID SNP ID
1 CARD14 p.Gly117Ser VAR_068224 rs281875215
2 CARD14 p.Glu138Ala VAR_068225 rs281875214
3 CARD14 p.Glu142Gly VAR_068226 rs281875213
4 CARD14 p.Glu142Lys VAR_068227 rs281875212
5 CARD14 p.Leu150Arg VAR_068228 rs146214639
6 CARD14 p.Arg69Trp VAR_078583 rs375624435
7 CARD14 p.Glu197Lys VAR_078588 rs200790561

ClinVar genetic disease variations for Psoriasis 2:

6 (show top 50) (show all 188)
# Gene Variation Type Significance SNP ID Assembly Location
1 CARD14 NM_024110.4(CARD14): c.349G> A (p.Gly117Ser) single nucleotide variant Pathogenic rs281875215 GRCh37 Chromosome 17, 78156589: 78156589
2 CARD14 NM_024110.4(CARD14): c.349G> A (p.Gly117Ser) single nucleotide variant Pathogenic rs281875215 GRCh38 Chromosome 17, 80182790: 80182790
3 CARD14 NM_024110.4(CARD14): c.349+5G> A single nucleotide variant Pathogenic rs587777763 GRCh38 Chromosome 17, 80182795: 80182795
4 CARD14 NM_024110.4(CARD14): c.349+5G> A single nucleotide variant Pathogenic rs587777763 GRCh37 Chromosome 17, 78156594: 78156594
5 CARD14 NM_024110.4(CARD14): c.425A> G (p.Glu142Gly) single nucleotide variant Pathogenic rs281875213 GRCh37 Chromosome 17, 78157787: 78157787
6 CARD14 NM_024110.4(CARD14): c.425A> G (p.Glu142Gly) single nucleotide variant Pathogenic rs281875213 GRCh38 Chromosome 17, 80183988: 80183988
7 CARD14 NM_024110.4(CARD14): c.424G> A (p.Glu142Lys) single nucleotide variant Pathogenic rs281875212 GRCh37 Chromosome 17, 78157786: 78157786
8 CARD14 NM_024110.4(CARD14): c.424G> A (p.Glu142Lys) single nucleotide variant Pathogenic rs281875212 GRCh38 Chromosome 17, 80183987: 80183987
9 CARD14 NM_024110.4(CARD14): c.1778T> A (p.Ile593Asn) single nucleotide variant Uncertain significance rs281875220 GRCh37 Chromosome 17, 78172317: 78172317
10 CARD14 NM_024110.4(CARD14): c.1778T> A (p.Ile593Asn) single nucleotide variant Uncertain significance rs281875220 GRCh38 Chromosome 17, 80198518: 80198518
11 CARD14 NM_024110.4(CARD14): c.185G> A (p.Arg62Gln) single nucleotide variant Benign rs115582620 GRCh37 Chromosome 17, 78155422: 78155422
12 CARD14 NM_024110.4(CARD14): c.185G> A (p.Arg62Gln) single nucleotide variant Benign rs115582620 GRCh38 Chromosome 17, 80181623: 80181623
13 CARD14 NM_024110.4(CARD14): c.2044C> T (p.Arg682Trp) single nucleotide variant Benign rs117918077 GRCh37 Chromosome 17, 78176044: 78176044
14 CARD14 NM_024110.4(CARD14): c.2044C> T (p.Arg682Trp) single nucleotide variant Benign rs117918077 GRCh38 Chromosome 17, 80202245: 80202245
15 CARD14 NM_024110.4(CARD14): c.2919C> G (p.Asp973Glu) single nucleotide variant Benign rs144285237 GRCh37 Chromosome 17, 78182048: 78182048
16 CARD14 NM_024110.4(CARD14): c.2919C> G (p.Asp973Glu) single nucleotide variant Benign rs144285237 GRCh38 Chromosome 17, 80208249: 80208249
17 CARD14 NM_024110.4(CARD14): c.449T> G (p.Leu150Arg) single nucleotide variant Likely benign rs146214639 GRCh37 Chromosome 17, 78157811: 78157811
18 CARD14 NM_024110.4(CARD14): c.449T> G (p.Leu150Arg) single nucleotide variant Likely benign rs146214639 GRCh38 Chromosome 17, 80184012: 80184012
19 CARD14 NM_024110.4(CARD14): c.536G> A (p.Arg179His) single nucleotide variant Uncertain significance rs199517469 GRCh37 Chromosome 17, 78157898: 78157898
20 CARD14 NM_024110.4(CARD14): c.536G> A (p.Arg179His) single nucleotide variant Uncertain significance rs199517469 GRCh38 Chromosome 17, 80184099: 80184099
21 CARD14 NM_024110.4(CARD14): c.599G> A (p.Ser200Asn) single nucleotide variant Likely benign rs114688446 GRCh37 Chromosome 17, 78157961: 78157961
22 CARD14 NM_024110.4(CARD14): c.599G> A (p.Ser200Asn) single nucleotide variant Likely benign rs114688446 GRCh38 Chromosome 17, 80184162: 80184162
23 CARD14 NM_024110.4(CARD14): c.589G> A (p.Glu197Lys) single nucleotide variant Uncertain significance rs200790561 GRCh37 Chromosome 17, 78157951: 78157951
24 CARD14 NM_024110.4(CARD14): c.589G> A (p.Glu197Lys) single nucleotide variant Uncertain significance rs200790561 GRCh38 Chromosome 17, 80184152: 80184152
25 CARD14 NM_024110.4(CARD14): c.881C> T (p.Ala294Val) single nucleotide variant Uncertain significance rs139466192 GRCh37 Chromosome 17, 78163589: 78163589
26 CARD14 NM_024110.4(CARD14): c.881C> T (p.Ala294Val) single nucleotide variant Uncertain significance rs139466192 GRCh38 Chromosome 17, 80189790: 80189790
27 CARD14 NM_024110.4(CARD14): c.299A> G (p.Tyr100Cys) single nucleotide variant Uncertain significance rs552779505 GRCh37 Chromosome 17, 78156539: 78156539
28 CARD14 NM_024110.4(CARD14): c.299A> G (p.Tyr100Cys) single nucleotide variant Uncertain significance rs552779505 GRCh38 Chromosome 17, 80182740: 80182740
29 CARD14 NM_024110.4(CARD14): c.960G> A (p.Glu320=) single nucleotide variant Benign rs144207494 GRCh37 Chromosome 17, 78163668: 78163668
30 CARD14 NM_024110.4(CARD14): c.960G> A (p.Glu320=) single nucleotide variant Benign rs144207494 GRCh38 Chromosome 17, 80189869: 80189869
31 CARD14 NM_024110.4(CARD14): c.1371G> A (p.Ser457=) single nucleotide variant Benign rs62074378 GRCh37 Chromosome 17, 78169004: 78169004
32 CARD14 NM_024110.4(CARD14): c.1371G> A (p.Ser457=) single nucleotide variant Benign rs62074378 GRCh38 Chromosome 17, 80195205: 80195205
33 CARD14 NM_024110.4(CARD14): c.1789C> T (p.Arg597Trp) single nucleotide variant Benign rs73429414 GRCh37 Chromosome 17, 78172328: 78172328
34 CARD14 NM_024110.4(CARD14): c.1789C> T (p.Arg597Trp) single nucleotide variant Benign rs73429414 GRCh38 Chromosome 17, 80198529: 80198529
35 CARD14 NM_024110.4(CARD14): c.2859G> A (p.Ala953=) single nucleotide variant Benign rs139969019 GRCh37 Chromosome 17, 78181988: 78181988
36 CARD14 NM_024110.4(CARD14): c.2859G> A (p.Ala953=) single nucleotide variant Benign rs139969019 GRCh38 Chromosome 17, 80208189: 80208189
37 CARD14 NM_024110.4(CARD14): c.556G> A (p.Ala186Thr) single nucleotide variant Uncertain significance rs190213582 GRCh38 Chromosome 17, 80184119: 80184119
38 CARD14 NM_024110.4(CARD14): c.556G> A (p.Ala186Thr) single nucleotide variant Uncertain significance rs190213582 GRCh37 Chromosome 17, 78157918: 78157918
39 CARD14 NM_024110.4(CARD14): c.709A> C (p.Asn237His) single nucleotide variant Benign rs114218658 GRCh38 Chromosome 17, 80188410: 80188410
40 CARD14 NM_024110.4(CARD14): c.709A> C (p.Asn237His) single nucleotide variant Benign rs114218658 GRCh37 Chromosome 17, 78162209: 78162209
41 CARD14 NM_024110.4(CARD14): c.2191G> A (p.Ala731Thr) single nucleotide variant Uncertain significance rs537086902 GRCh38 Chromosome 17, 80202392: 80202392
42 CARD14 NM_024110.4(CARD14): c.2191G> A (p.Ala731Thr) single nucleotide variant Uncertain significance rs537086902 GRCh37 Chromosome 17, 78176191: 78176191
43 CARD14 NM_024110.4(CARD14): c.2193G> A (p.Ala731=) single nucleotide variant Benign rs35692270 GRCh38 Chromosome 17, 80202394: 80202394
44 CARD14 NM_024110.4(CARD14): c.2193G> A (p.Ala731=) single nucleotide variant Benign rs35692270 GRCh37 Chromosome 17, 78176193: 78176193
45 CARD14 NM_024110.4(CARD14): c.2772C> T (p.His924=) single nucleotide variant Benign rs146356100 GRCh38 Chromosome 17, 80207050: 80207050
46 CARD14 NM_024110.4(CARD14): c.2772C> T (p.His924=) single nucleotide variant Benign rs146356100 GRCh37 Chromosome 17, 78180849: 78180849
47 CARD14 NM_024110.4(CARD14): c.203T> C (p.Met68Thr) single nucleotide variant Uncertain significance rs773633754 GRCh38 Chromosome 17, 80181641: 80181641
48 CARD14 NM_024110.4(CARD14): c.203T> C (p.Met68Thr) single nucleotide variant Uncertain significance rs773633754 GRCh37 Chromosome 17, 78155440: 78155440
49 CARD14 NM_024110.4(CARD14): c.378G> A (p.Glu126=) single nucleotide variant Benign rs138552007 GRCh38 Chromosome 17, 80183941: 80183941
50 CARD14 NM_024110.4(CARD14): c.378G> A (p.Glu126=) single nucleotide variant Benign rs138552007 GRCh37 Chromosome 17, 78157740: 78157740

Expression for Psoriasis 2

Search GEO for disease gene expression data for Psoriasis 2.

Pathways for Psoriasis 2

Pathways related to Psoriasis 2 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
10.47 ADA HIF1A

GO Terms for Psoriasis 2

Biological processes related to Psoriasis 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.16 ADA HIF1A
2 negative regulation of apoptotic process GO:0043066 9.13 ADA CARD14 HIF1A
3 negative regulation of thymocyte apoptotic process GO:0070244 8.62 ADA HIF1A

Sources for Psoriasis 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....